Exchange: NASDAQ·Updated 07:30 PM EST
ESTA logo

ESTA Establishment Labs Holdings Inc

$69.14
$0.47
(0.68%)
Today
Closed $69.14
$0.00
(0.00%)
After Hours
Reported EarningsOct 29
Mkt Cap$2.06B
Vol464,239.00

About ESTA

Establishment Labs Holdings, Inc. engages in the manufacturing and marketing of medical devices for aesthetic and reconstructive plastic surgery. Its brands include Motiva Implants, SilkSurface, SmoothSilk, VelvetSurface, ProgressiveGel, TrueMonobloc, BluSeal, Divina, Ergonomix, Ergomonix2, Ergonomix2 Diamond, Mia Femtech, MotivaImagine, GEM, Zen, Preservé, etc. The company was founded by Juan Jose Chacon-Quiros in 2004 and is headquartered in Austin, TX.
39

Bearish Sentiment

How do you feel about ESTA?

njbugatti
$ESTA Jennifer Lawrence - new recipient of Motiva breast implants via Dr Steven Teitelbaum - Dr has strong history of public comments about ESTA and Motiva!
4
Lambster2
$ESTA TD Cowen cuts PT to 95. Very bullish report. PT reduction is "to account for the multiple contraction experienced by the high growth smid cap Medical Devices peer group." Establishment Labs (NASDAQ: ESTA) Buy (1) Price Target: $95.00 (Prior $117.00) 3Q Preview: We Expect The U.S. To Lead The Way To Another Beat And Raise THE TD COWEN INSIGHT We expect ESTA to deliver a 3Q revenue beat across both the US and OUS franchises, with the Street's OUS sales decline estimate proving conservative. FDA approval for the recon indication should add a near-term catalyst alongside the 3Q beat and revenue guidance raise, while GM expansion and an improving profitability trajectory should be well received. Reiterate Buy, PT to $95 from $117.
3
YouOnlyLiveTwice
$ESTA Now that a large majority of the adult women population are on GLP the next move is to fix the breasts …. They will be acquired
2
Lambster2
$ESTA Still my largest holding. Establishment Labs (NASDAQ: ESTA) Buy (1) Price Target: $95.00 Motiva + Ergonomix Set to Capture Significant Share in U.S. Breast Recon THE TD COWEN INSIGHT We view breast reconstruction as an underappreciated growth opportunity for ESTA that could rival U.S. augmentation in revenue potential. Motiva + Ergonomix's differentiated softness, low rippling propensity, and favorable tissue interaction, complemented by FLORA and future Ergonomix2 optionality, could support rapid share capture.
1
Lambster2
$ESTA Establishment Labs (NASDAQ: ESTA) Buy (1) Price Target: $95.00 3Q/4Q Momentum In-tact with Catalysts Around the Corner THE TD COWEN INSIGHT ESTA shares have retraced higher with international distributor concerns now somewhat assuaged and U.S. momentum in-tact. Looking forward, we are bullish given the strong start to 4Q, multiple catalysts around the corner (additional sizes, U.S. sales force expansion contribution, and reconstruction), and positive 2027 FCF on the come. Reiterate Buy and $95 PT.
1
TriGuy8542
$ESTA this going down makes bsolutrly no sense against the market. Viewing this period of time as a great period to accumulate cheap shares.
1
TriGuy8542
$ESTA I can’t see “watchers,” but it must be sub 1k. I personally didn’t find this company and unsure if I even would except if I used AI. The world will be an interesting place once people start using agents to find niche moving in the right macro direction.
1
gabrielillo
$ESTA do not miss this boat guys. ER coming in hot at a time when this stock has been beaten up. We know high int rates have not been favorable for a company in the verge of becoming cash flow positive but this is precisely why we have this opportunity to make 50% short-term upside.
1
shoc24
$ESTA reported earnings before the open: GAAP EPS of −$0.35 vs. −$0.26 estimated, a miss of 36.3%. I used Stock Meadow to review the results.
StocktwitsEarnings
$ESTA Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.35 up 7.89% YoY • Reported revenue of $71.99M up 33.86% YoY • Establishment Labs raised full-year 2026 revenue expectations to more than $274M, with adjusted gross margin approximately 70.7%, adjusted operating expenses of $195M to $200M unchanged, and positive adjusted EBITDA for the full year.
shoc24
$ESTA is estimated to report earnings tomorrow before the open. I used Stock Meadow’s earnings dashboard to review its history: ESTA has beaten EPS estimates in 4 of its last 8 reports.

Advertisement|Remove ads.